Movymia (teriparatide biosimilar) / Stada - LARVOL DELTA

Utilization of Best-Value Medicines for Teriparatide in the Irish Healthcare Setting (ISPOR-EU 2025) - "As of June 2025, there are five medicinal products containing teriparatide available on the national reimbursement list in Ireland; the reference medicine, Forsteo®, three biosimilar medicines, Movymia®, Sondelbay® and Terrosa®, and a hybrid medicinal product, Tetridar®. The implementation of BVMs as part of Health Technology Management (HTM) enhances the safe, effective and cost-effective use of medicines and products whilst also controlling utilisation and expenditure. Using this approach, a significant increase in the uptake rate of teriparatide BVMs has been achieved."

ESECTO: Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile. (clinicaltrials.gov) - P=N/A | N=188 | Active, not recruiting | Sponsor: STADA, Spain

New trial • Osteoporosis • Rheumatology

"Analytical similarity assessment of teriparatide biosimilar Terrosa: Terrosa and Movymia both developed under the code name RGB10 were the first biosimilars of Eli Lillys osteoporosis biological ForteoForsteo teriparatide in Europe. Gedeon… https://t.co/4ifeJEQZOH #EliLilly" (@Lilly_bio)